Dupilumab for Allergic Contact Dermatitis
Trial Summary
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications before joining. You cannot have used systemic immune-regulating medications like azathioprine or methotrexate within 3 months, or biologic agents like TNF inhibitors within 4 months before the trial starts. Additionally, you must not have used cyclosporine or prednisone within 1 month, or topical corticosteroids within 1 week before the trial.
What data supports the effectiveness of the drug Dupilumab for allergic contact dermatitis?
Dupilumab has been shown to be effective in treating atopic dermatitis, a similar skin condition, by targeting specific proteins involved in inflammation. It has a favorable safety profile with few reversible side effects, suggesting potential effectiveness for allergic contact dermatitis as well.12345
Is dupilumab generally safe for humans?
How is the drug Dupilumab unique for treating allergic contact dermatitis?
Dupilumab is unique because it is a monoclonal antibody that targets the IL-4 and IL-13 pathways, which are involved in allergic inflammation. This mechanism is different from traditional treatments that often focus on topical therapies, making it a novel option for conditions like allergic contact dermatitis.125810
What is the purpose of this trial?
The aim of this study is to investigate the effects of dupilumab on allergic contact dermatitis.
Eligibility Criteria
Adults with strong allergic reactions to contact allergens, diagnosed with allergic contact dermatitis not responding well to topical treatments and avoidance. They must be able to consent and participate fully in the study. Excluded are those on recent immune medications, pregnant or breastfeeding women not using birth control, residents outside certain states, unable to use Zoom, prior dupilumab users, or with conditions that could affect the trial.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive dupilumab for 10 weeks, with initial dose of 600 mg followed by 300 mg every 2 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Dupilumab
Dupilumab is already approved in United States, European Union for the following indications:
- Atopic dermatitis
- Asthma
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis
- Atopic dermatitis
- Asthma
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
Regeneron Pharmaceuticals
Industry Sponsor
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer since 1988
MD and PhD in Medicine
George Yancopoulos
Regeneron Pharmaceuticals
Chief Medical Officer since 1997
MD from Harvard Medical School